Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

1. Pivot, X.
2. Pegram, M.
3. Cortes, J.
4. Lüftner, D.
5. Lyman, G.H.
6. Curigliano, G.
7. Bondarenko, I.
8. Yoon, Y.C.
9. Kim, Y.
10. Kim, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.EJCA.2019.07.015 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus